Non-invasive embryo screening fails to boost live birth rates
A clinical trial in China compared non-invasive preimplantation genetic testing for aneuploidy (niPGT-A) with standard morphology-based embryo selection. The niPGT-A group had similar ongoing pregnancy and live birth rates, but significantly fewer early miscarriages. The researchers concluded there is insufficient evidence to recommend routine use of niPGT-A in good-prognosis patients.
The trial enrolled 1,152 women aged 35-42 across 13 Chinese fertility centres, comparing niPGT-A against standard morphology-based embryo selection. While ongoing pregnancy rates (38.7% vs 36.8%) and live birth rates (37% vs 35.5%) showed no statistically significant difference, early miscarriages before 12 weeks were notably lower in the niPGT-A group (18% vs 25.2%).
The study did not include a conventional PGT-A arm, meaning direct comparisons between invasive and non-invasive approaches remain unexplored. Regulatory bodies including the HFEA and ASRM have already questioned PGT-A's routine value, and this trial adds evidence that niPGT-A offers no pregnancy-rate advantage for good-prognosis patients, though miscarriage reduction may warrant further investigation.
This trial could influence clinical decisions for IVF patients aged 35-42, who may face additional costs and testing without clear pregnancy-rate benefits. The reduced early miscarriage rate may offer some reassurance, but patients could weigh whether non-invasive screening justifies its expense when live birth outcomes appear similar. Fertility clinics may reconsider how they present niPGT-A options, and future research might explore which patient subgroups could genuinely benefit from miscarriage reduction.